These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 11505710)
1. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Ritt MJ; Hillebrand-Haverkort ME; ten Veen JH Acta Chir Plast; 2001; 43(2):54-6. PubMed ID: 11505710 [TBL] [Abstract][Full Text] [Related]
2. [Facial lipodystrophy in patients with HIV infections troublesome to treat]. Walther RA Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531 [TBL] [Abstract][Full Text] [Related]
3. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome. Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090 [TBL] [Abstract][Full Text] [Related]
4. [Pulmonary complications in patients with AIDS]. Oka S Kekkaku; 2002 Jan; 77(1):37-40. PubMed ID: 11855078 [TBL] [Abstract][Full Text] [Related]
5. HIV-associated facial lipoatrophy--review of current therapy options. Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH; Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554 [TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy? Goulbourne CN; Vaux DJ Biochem Soc Trans; 2010 Feb; 38(Pt 1):292-6. PubMed ID: 20074077 [TBL] [Abstract][Full Text] [Related]
7. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)]. Calza L; Manfredi R; Chiodo F Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680 [TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy. Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308 [TBL] [Abstract][Full Text] [Related]
9. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. Kong HH; Myers SA Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613 [TBL] [Abstract][Full Text] [Related]
10. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Terry L; Sprinz E; Stein R; Medeiros NB; Oliveira J; Ribeiro JP Med Sci Sports Exerc; 2006 Mar; 38(3):411-7. PubMed ID: 16540826 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343 [TBL] [Abstract][Full Text] [Related]